Haemophilia treatment in 2030

被引:7
作者
Berntorp, E. [1 ]
机构
[1] Lund Univ, Ctr Thrombosis & Haemostasis, Malmo, Sweden
关键词
haemophilia; inhibitor; prophylaxis; RECOMBINANT FACTOR-VIII; COAGULATION-FACTOR IX; FC FUSION PROTEIN; SECONDARY PROPHYLAXIS; RIX-FP; PHASE-3; INHIBITORS; SAFETY; PHARMACOKINETICS; HEMOSTASIS;
D O I
10.1111/hae.13025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as well as dilemmas. Today, the issue of inhibitors overshadows the entire haemophilia community together with lack of treatment for large parts of the world's persons with haemophilia. AimsThe aim of this paper was to provide a perspective on haemophilia treatment in 2030 and its provenance. MethodsLiterature review on history, treatment of haemophilia today as well as of emerging therapies give a base for the author's opinion on haemophilia treatment in 2030. ResultsDevelopment of haemophilia treatment has virtually exploded during the last decade and a number of new clotting factor concentrates and alternative approaches are in the pipeline. ConclusionThe collection of treatment resources that we can see on the horizon gives hope that each person with haemophilia will get the care needed in 2030. The products used will be directed by individual needs and tailored to regional and local situations.
引用
收藏
页码:15 / 19
页数:5
相关论文
共 40 条
  • [1] Aledort L M, 1979, Southeast Asian J Trop Med Public Health, V10, P280
  • [2] FVIII inhibitors: pathogenesis and avoidance
    Astermark, Jan
    [J]. BLOOD, 2015, 125 (13) : 2045 - 2051
  • [3] The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
    Astermark, Jan
    Donfield, Sharyne M.
    Gomperts, Edward D.
    Schwarz, John
    Menius, Erika D.
    Pavlova, Anna
    Oldenburg, Johannes
    Kessing, Bailey
    DiMichele, Donna M.
    Shapiro, Amy D.
    Winkler, Cheryl A.
    Berntorp, Erik
    [J]. BLOOD, 2013, 121 (08) : 1446 - 1454
  • [4] History of prophylaxis
    Berntorp, E.
    [J]. HAEMOPHILIA, 2013, 19 (02) : 163 - 165
  • [5] Modern haemophilia care
    Berntorp, Erik
    Shapiro, Amy D.
    [J]. LANCET, 2012, 379 (9824) : 1447 - 1456
  • [6] Beutel Karin, 2009, Hamostaseologie, V29, P155
  • [7] CHRISTMAS DISEASE - A CONDITION PREVIOUSLY MISTAKEN FOR HAEMOPHILIA
    BIGGS, R
    DOUGLAS, AS
    MACFARLANE, RG
    DACIE, JV
    PITNEY, WR
    MERSKEY, C
    OBRIEN, JR
    [J]. BRITISH MEDICAL JOURNAL, 1952, 2 (4799) : 1378 - 1382
  • [8] Blomback B., 2007, Compr Biochem, V45, P209, DOI DOI 10.1016/S0069-8032(07)45006-9
  • [9] Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)
    Chitlur, M.
    Warrier, I.
    Rajpurkar, M.
    Lusher, J. M.
    [J]. HAEMOPHILIA, 2009, 15 (05) : 1027 - 1031
  • [10] Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
    Chowdary, P.
    Lethagen, S.
    Friedrich, U.
    Brand, B.
    Hay, C.
    Karim, F. Abdul
    Klamroth, R.
    Knoebl, P.
    Laffan, M.
    Mahlangu, J.
    Miesbach, W.
    Nielsen, J. Dalsgaard
    Martin-Salces, M.
    Angchaisuksiri, P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 743 - 754